P901: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN LENALIDOMIDE–PRETREATED MULTIPLE MYELOMA: A SUBANALYSIS OF OPTIMISMM BY FRAILTY

• A. Oriol,
• M. Dimopoulos,
• F. Schjesvold,
• M. Beksac,
• M. Yagci,
• A. Larocca,
• S. Guo,
• Y. Mu,
• K. Hong,
• S. Dhanasiri,
• P. Richardson,
• K. Weisel

Affiliations

A. Oriol

1 Hematology Department, Institut Català d’Oncologia, Barcelona, Spain

M. Dimopoulos

2 National and Kapodistrian University, Athens, Greece

F. Schjesvold

3 Oslo Myeloma Center, Department of Hematology, Oslo University Hospital

M. Beksac

5 Ankara Üniversitesi Tip Fakültes

M. Yagci

6 Gazi University Medical Faculty, Ankara, Turkey

A. Larocca

7 SSD Clinical trials in onco-ematologia e mieloma multiplo, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

S. Guo

8 Evidera, Waltham

Y. Mu

8 Evidera, Waltham

K. Hong

9 Bristol Myers Squibb, Princeton, United States of America

S. Dhanasiri

10 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland

P. Richardson

11 Dana-Farber Cancer Institute, Boston, United States of America

K. Weisel

12 University Medical Center Hamburg-Eppendorf, Hamburg, Germany